- Email: [email protected]
Information for category 1 CME credit
T HE J OURNAL OF
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.mosby.com/jaci. The accompanying tests may only be submitted online at www.mosby.com/jaci. Fax or other copies will not be accepted. Date of Original Release: August 2005. Credit may be obtained for these courses until July 31, 2006. Copyright Statement: Copyright Ó 2005-2006. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for up to 1.0 hour in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he or she actually spent in the educational activity.
CME article
CME article
‘‘Innate immune responses to infection’’ (page 241)
‘‘EBV the prototypical human tumor virus—just how bad is it?’’ (page 251)
List of Design Committee Members: Author: Michael F. Tosi, MD Activity Objectives 1. To achieve a greater and more current understanding of the nature and scope of innate immune responses to infection. 2. To develop an enhanced appreciation for the range of interactions among various components of innate immunity. 3. To be able to appreciate the specific microbial targets of specific effector mechanisms of innate immunity. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Michael F. Tosi has no significant relationships to disclose.
List of Design Committee Members: Author: David A. Thorley-Lawson, PhD Activity Objectives 1. To understand that EBV uses mature B cell biology to establish latency, persist, and replicate. 2. To understand that even though EBV is so widespread and apparently benign, it is potentially life-threatening. 3. To understand that EBV evolved the capacity to make cells grow because it is an essential part of the mechanism for establishing latency in resting cells that are not pathogenic. 4. To understand that EBV-associated tumors arise from different stages in the life cycle of latently infected B cells and that disruption of the immune response is an important component in the development of all of the EBV-associated lymphomas. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: David A. Thorley-Lawson has equity ownership in EBVax.
32A August 2005
J ALLERGY CLIN IMMUNOL
Allergy Clinical Immunology AND
INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review articles in this issue. Please note the following instructions. Method of Physician Participation in Learning Process: The core material for these activities can be read in this issue of the Journal or online at the JACI Web site: www.mosby.com/jaci. The accompanying tests may only be submitted online at www.mosby.com/jaci. Fax or other copies will not be accepted. Date of Original Release: August 2005. Credit may be obtained for these courses until July 31, 2006. Copyright Statement: Copyright Ó 2005-2006. All rights reserved. Overall Purpose/Goal: To provide excellent reviews on key aspects of allergic disease to those who research, treat, or manage allergic disease. Target Audience: Physicians and researchers within the field of allergic disease. Accreditation/Provider Statements and Credit Designation: The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates these educational activities for up to 1.0 hour in category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he or she actually spent in the educational activity.
CME article
CME article
‘‘Innate immune responses to infection’’ (page 241)
‘‘EBV the prototypical human tumor virus—just how bad is it?’’ (page 251)
List of Design Committee Members: Author: Michael F. Tosi, MD Activity Objectives 1. To achieve a greater and more current understanding of the nature and scope of innate immune responses to infection. 2. To develop an enhanced appreciation for the range of interactions among various components of innate immunity. 3. To be able to appreciate the specific microbial targets of specific effector mechanisms of innate immunity. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: Michael F. Tosi has no significant relationships to disclose.
List of Design Committee Members: Author: David A. Thorley-Lawson, PhD Activity Objectives 1. To understand that EBV uses mature B cell biology to establish latency, persist, and replicate. 2. To understand that even though EBV is so widespread and apparently benign, it is potentially life-threatening. 3. To understand that EBV evolved the capacity to make cells grow because it is an essential part of the mechanism for establishing latency in resting cells that are not pathogenic. 4. To understand that EBV-associated tumors arise from different stages in the life cycle of latently infected B cells and that disruption of the immune response is an important component in the development of all of the EBV-associated lymphomas. Recognition of Commercial Support: This CME activity has not received external commercial support. Disclosure of Significant Relationships with Relevant Commercial Companies/Organizations: David A. Thorley-Lawson has equity ownership in EBVax.
32A August 2005
J ALLERGY CLIN IMMUNOL